CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 122 enrolled
Drug / intervention
Intravenous Nitroglycerin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01999517
NCT01999517Phase 4Completed

Contrast Nephropathy and Nitrates

Mt. Sinai Medical Center, Miami·interventional·Posted Dec 3, 2013·Updated Oct 29, 2019

In Brief

A Phase 4 clinical trial evaluating Intravenous Nitroglycerin and IV Fluids for Contrast Induced Nephropathy. Completed, enrolled 122 participants across 1 site.

Detailed Summary

Contrast-induced nephropathy (CIN) is a complication of percutaneous coronary angiography that occurs in about 10 to 20% of patients exposed to contrast media. Iodinated contrast is used during coronary angiography to see the coronary arteries. It has been shown that exposure to this agent may cause kidney injury. CIN usually goes away on its own but in some high risk patients it progresses into renal failure. This research study offers a new possible option to prevent CIN. We propose that if intravenous nitroglycerin is given before the procedure it may lower the chances of developing contrast-induced nephropathy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 3, 2013
Enrollment StartJun 1, 2013
Primary CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 12.6 years ago

Interventions

Intravenous Nitroglycerindrug

IV Fluidsdrug